SEPT9基因在人肝细胞癌侵袭转移中的作用

肝脏 ›› 2019, Vol. 24 ›› Issue (8): 910-914.

SEPT9基因在人肝细胞癌侵袭转移中的作用

邓冲, 郭德良, 谢雄伟

448000 湖北荆门荆门市第一人民医院普外科

收稿日期:2018-12-30 发布日期:2020-04-01
通讯作者: 谢雄伟
基金资助:
SEPT9基因在人肝细胞癌侵袭转移中的作用研究(2017CFB777)

Received:2018-12-30 Published:2020-04-01

摘要/Abstract

摘要： 目的研究SEPT9基因对人肝癌细胞侵袭转移的影响。方法通过westernblot法筛选SEPT9蛋白高表达肝癌细胞系,慢病毒转染沉默后检测细胞SEPT9蛋白表达量,通过EdU染色检测sh-SEPT9对肝癌细胞增殖的影响;Transwell和划痕实验检测沉默SEPT9表达后肝癌细胞的侵袭能力和迁移能力;westernblot分析沉默SEPT9表达对肝癌细胞HIF-1α、Ki67、PCNA、MMP-9、VEGF、Vimentin, N-cadherin、E-cadherin蛋白表达影响。结果 westernblot显示SEPT9蛋白在肝癌HepG2细胞存在高表达,慢病毒转然能够获得稳定遗传的HepG2-SEPT9-shRNA细胞系,sh-SEPT9转然后,EdU染色显示HepG2细胞增殖受到明显抑制(P<0.05),细胞的侵袭能力和迁移能力显著降低(P<0.05);HepG2细胞Ki67、PCNA、Vimentin、N-cadherin、HIF-1α、MMP-9及VEGF表达量明显降低,E-cadherin的蛋白水平明显上升(P<0.05)。结论 SEPT9基因通过增强肝癌HepG2细胞的EMT机制,促进肝癌HepG2细胞的侵袭转移。

关键词: SEPT9基因, 基因沉默, 侵袭转移, 上皮细胞-间充质转化

邓冲, 郭德良, 谢雄伟. SEPT9基因在人肝细胞癌侵袭转移中的作用[J]. 肝脏, 2019, 24(8): 910-914.

参考文献

[1] Li L, Wang H. Heterogeneity of liver cancer and personalized therapy.. Cancer Letters, 2016, 379:191-197.
[2] Wan S , Meyer AS , Weiler SME . Cytoplasmic localization of the cell polarity factor Scribble supports liver tumor formation and tumor cell invasiveness.. Hepatology, 2018, 67:1842-1856.
[3] Scott M,Hyland PL,Mcgregor G,et al.Multimodality expression profiling shows SEPT 9 to be overexpressed in a wide range of human tumours. Oncogene,2005,24:4688-4700.
[4] Oussalah A, Rischer S, Bensenane M, et al. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. Ebiomedicine, 2018,4:138-142.
[5] Bai X , Karasmanis EP , Spiliotis ET . Septin 9 interacts with kinesin KIF17 and interferes with the mechanism of NMDA receptor cargo binding and transport. Mol Biol Cell, 2016, 27:897-906.
[6] Reed S O , Lamason R , Risca V , et al. Rickettsia Actin-Based Motility Occurs in Distinct Phases Mediated by Different Actin Nucleators. Curr Biol, 2014, 24:98-103.
[7] Song L,Yu H,Jia J,et al. A systematic review of the performance of the SEPT 9 gene methylation assay in colorectal cancer screening,monitoring,diagnosis and prognosis. Cancer Biomark, 2017,18:425-432.
[8] 刘文, 狄建忠, 邹扬,等. SEPT9基因与恶性肿瘤关系的研究进展. 肿瘤, 2010, 30:798-801.
[9] Flomerfelt FA, Gress RE. Analysis of Cell Proliferation and Homeostasis Using EdU Labeling. Methods Mol Biol, 2016, 1323:211-216.
[10] Carvalho MI, Pires I, Prada J, et al. Ki-67 and PCNA Expression in Canine Mammary Tumors and Adjacent Nonneoplastic Mammary Glands: Prognostic Impact by a Multivariate Survival Analysis. Vet Pathol, 2016, 53:1138-1146.
[11] Wang Y, Chen T, Huang H, et al. miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma. Oncotarget, 2017, 8:20133-20144.
[12] 童宇洋, 许晓琳, 罗葆明. 上皮-间质转化在肝癌非手术治疗后促进残癌侵袭、转移的研究进展. 中国介入影像与治疗学, 2016, 13:449-452.
[13] Li FJ, Surolia R, Li H, et al. Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.. J Immunol, 2017, 199:1596-1605.
[14] Labernadie A, Kato T, Brugués A, et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol, 2017, 19:224-231.
[15] Chang YC , Chan YC , Chang WM , et al. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression. Cancer Lett, 2017, 10:28-36.
[16] Jablonska-Trypuć A, Matejczyk M,et al. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem, 2016, 23:177-183.